NSCLC
Conditions
Brief summary
This study is an open-label Phase II clinical trial to evaluate the safety and efficacy of SHR-A1921 or SHR-A2009 in patients with advanced NSCLC who progressed after standard therapy.
Interventions
DRUGSHR-A2009
Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
DRUGSHR-A1921
Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Sponsors
Henan Cancer Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntary participation and written informed consent; 2. Aged 18-75 years (inclusive), males and females; 3. Has a histologically or cytologically confirmed diagnosis of metastatic NSCLC (according to 8th AJCC/UICC Classification); 4. Has failed to standard therapy and disease progressed after antibody-conjugated drugs therapy; 5. Has at least 1 measurable lesion per RECIST 1.1; 6. Patients with ECOG score of 0-1; 7. Life expectancy ≥12 weeks; 8. Have adequate organ function; 9. Participants agrees to use contraception, and be abstinent from heterosexual intercourse during the treatment period and for ≥180 days after the last dose of study treatment.
Exclusion criteria
1. Histologically or cytologically confirmed presence of small-cell lung cancer or other benefit-limiting tumor components; 2. Untreated brain metastasis or accompanied by meningeal metastases, spinal cord compression; 3. Cancerous ascites, pleural effusion or pericardial effusion with clinical symptoms; 4. Subjects who have received systemic anti-tumor treatments prior to the initiation of the study treatment; 5. Has received major organ surgery or high-intensity thoracic radiotherapy within before first dose of study therapy； 6. Has a history of a second malignancy; 7. Has a history of non-infectious ILD/pneumonitis that required steroids, or has current ILD/pneumonitis; 8. Subjects with active pulmonary tuberculosis infection； 9. Serious infection before the first dose； 10. Uncontrolled cardiac diseases or symptoms; 11. Arterial/venous thrombosis events occurred before the first dose； 12. Hypertension that can not be well controlled through antihypertensive drugs，previous hypertensive crisis or hypertensive encephalopathy； 13. Has a history of active chronic enteritis; 14. Has a history of bleeding prior to the initiation of the study treatment; 15. History of immunodeficiency disease or organ transplant; 16. Subjects with active hepatitis B or active hepatitis C; 17. Has unresolved toxicities from previous anticancer therapy; 18. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-A1921or SHR-A2009; 19. Subjects with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of the patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | up to 12 months | Assessed by Investigator According to RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival (OS) | up to 24 months | OS is the time from the date of first dose until the date of death by any cause. |
| Duration of response(DoR ) | up to 12 months | Assessed by Investigator According to RECIST v1.1 |
| Progression-free survival (PFS) | up to 12 months | Assessed by Investigator According to RECIST v1.1 |
| Time to Response (TTR) | up to 12 months | Assessed by Investigator According to RECIST v1.1 |
| The incidence and severity of adverse events (AEs) | from Day1 to 90 days after last dose | Rated based on CTCAE V5.0 |
| Disease control rate (DCR) | up to 12 months | Assessed by Investigator According to RECIST v1.1 |
Countries
China
Contacts
Primary ContactQiming Wang, professor
Backup ContactZhen He, professor
Outcome results
None listed